At Transcode Therapeutics' 2024 Annual Meeting held on June 13, shareholders voted against the proposed reverse stock split that would have allowed for a ratio between 1-for-2 and 1-for-40. The meeting saw participation from 2,392,577 shares out of 6,108,053 eligible voting shares.Shareholders approved most other proposals, including the election of four directors (Philippe Calais, Thomas Fitzgerald, Erik Manting, and Magda Marquet), the amendment to increase shares under the 2021 Stock Option and Incentive Plan by 3 million shares, and the appointment of WithumSmith+Brown as the independent auditor for FY2024.The Adjournment Proposal was approved with 1,289,670 votes in favor, though no corresponding motion was made to adjourn the meeting following the approval. The rejected reverse stock split proposal received 1,018,164 votes in favor versus 1,277,915 against.

At Transcode Therapeutics' 2024 Annual Meeting held on June 13, shareholders voted against the proposed reverse stock split that would have allowed for a ratio between 1-for-2 and 1-for-40. The meeting saw participation from 2,392,577 shares out of 6,108,053 eligible voting shares.Shareholders approved most other proposals, including the election of four directors (Philippe Calais, Thomas Fitzgerald, Erik Manting, and Magda Marquet), the amendment to increase shares under the 2021 Stock Option and Incentive Plan by 3 million shares, and the appointment of WithumSmith+Brown as the independent auditor for FY2024.The Adjournment Proposal was approved with 1,289,670 votes in favor, though no corresponding motion was made to adjourn the meeting following the approval. The rejected reverse stock split proposal received 1,018,164 votes in favor versus 1,277,915 against.